From Bench to Bedside The Evolution of Genomics and Its Implications for the Current and Future Management of Multiple Myeloma

The summation of 20 years of biological studies and the comprehensive analysis of more than 1000 multiple myeloma genomes with data linked to clinical outcome has enabled an increased understanding of the pathogenesis of multiple myeloma in the context of normal plasma cell biology. This novel data have facilitated the identification of prognostic markers and targets suitable for therapeutic manipulation. The challenge moving forward is to translate this genetic and biological information into the clinic to improve patient care. This review discusses the key data required to achieve this and provides a framework within which to explore the use of response-adapted, biologically targeted, molecularly targeted, and risk-stratified therapeutic approaches to improve the management of patients with multiple myeloma.

Automated summary

The culmination of 20 years of biological studies and analysis provides a better understanding of the pathogenesis of multiple myeloma, leading to the identification of therapeutic targets and prognostic markers. The challenge ahead is translating this information into clinical practice to enhance patient care.